Overview
- Aristotle reported a first‑quarter return of -4.45% for its Core Equity Fund versus -4.33% for the S&P 500, noting allocation hurt results while stock picking helped.
- Boston Scientific weighed on performance as investors questioned how long its fast growth in electrophysiology and the Watchman heart device can last.
- Trial data for Watchman from the CHAMPION‑AF study were positive but fell short of market hopes, and the fund said a rebound in electrophysiology results at Q1 earnings is the next proof point.
- The fund opened a new position in Coherent, calling it a vertically integrated photonics supplier positioned for AI data‑center demand with validation from a partnership with NVIDIA and a serviceable market projected to top $70 billion by 2030.
- Aristotle highlighted its tilt toward long‑run growth drivers, while noting Boston Scientific posted 11.6% year‑over‑year revenue growth to $5.203 billion in Q1 even as investor skepticism persisted.